Form 4: Vericel Corp Director Alan Rubino Reports Stock Transactions

Director Alan Rubino reports acquisition of Vericel Corp common stock through vesting of restricted stock units and grant of stock options.

Summary

• On April 30, 2025, Alan Rubino, a director of Vericel Corp, reported transactions involving the company's stock.
• Rubino acquired 3,200 shares of common stock through the vesting of Restricted Stock Units (RSUs) granted on May 1, 2024.
• He also received a grant of 8,000 stock options with an exercise price of $38.02, vesting monthly over one year and expiring on April 30, 2035.
• Additionally, 3,200 RSUs were granted, vesting on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025.
• Following these transactions, Rubino directly owns 45,994 shares of Vericel Corp common stock and 8,000 stock options, and 3,200 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating standard compensation practices. There's no indication of unusual or concerning activity.

Positives

• The vesting of RSUs and grant of stock options to a director could be seen as an incentive aligning the director's interests with those of the shareholders.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Stock option grants and RSU awards are common compensation practices for directors and executives in publicly traded companies, particularly in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation to align management interests with shareholder value.
• The vesting schedules and exercise prices are generally structured to incentivize long-term performance and retention.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment as they demonstrate the director's continued investment in the company.

Key Dates

Keywords

Vericel Corp, Alan Rubino, Director, Stock Options, Restricted Stock Units, VCEL, Beneficial Ownership, Form 4